Sirtex Medical
Sirtex makes SIR-Spheres, yttrium-90 resin microspheres used for radioembolisation of liver tumours.
Overview
Sirtex Medical, based in Woburn, Massachusetts, and owned by China Grand Pharmaceutical, makes SIR-Spheres, yttrium-90 resin microspheres used for radioembolisation of liver tumours. SIR-Spheres are indicated in the United States for unresectable colorectal cancer metastatic to the liver and carry a CE mark for hepatocellular carcinoma, with the DOORwaY90 trial supporting a US indication in liver cancer, and they compete with Boston Scientific's TheraSphere glass microspheres. Nuclide links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation technology record. Whether radioembolisation earns a place alongside systemic immunotherapy combinations in liver cancer, rather than being displaced by them, is the open question. The technology page covers the evidence.
Scorecard
All companies- approved products +6
- modalities +2
- regions +1
- registry trials +9
Tiny radioactive beads are injected through a small tube into the artery that feeds the liver. They lodge in the tumour and give it radiation from the inside, mostly sparing the rest of the liver.
Similar pages
not linked directly; found by shared links- IndicationIntermediate hepatocellular carcinoma (BCLC B)
Shares Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma, Quirem Medical, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- TrialSARAH and SIRveNIB
Shares Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- CompanyBoston Scientific
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Quirem Medical, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- AgentHolmium-166 microspheres
Shares Yttrium-90 resin microspheres, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- IsotopeHolmium-166
Shares Quirem Medical, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Quirem Medical, Hepatocellular carcinoma, Yttrium-90.
- AgentYttrium-90 glass microspheres
Shares Yttrium-90 resin microspheres, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.